Vulvar Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Vulvar cancer, also known as vulval cancer or cancer of the vulva, originates in the tissues of a woman's external genital area. It is relatively uncommon and can manifest in various parts of the vulva, including the labia majora and minora, clitoris, vaginal opening, and perineum (the area between the vulva and anus). The most prevalent type of vulvar cancer is squamous cell carcinoma (SCC), which develops from the squamous cells lining the vulvar surface. Other less common types include adenocarcinoma, melanoma, and basal cell carcinoma. Typical symptoms of vulvar cancer may include itching, burning, soreness, or pain in the vulva, the presence of a lump, sore, swelling, or wart-like growth, changes in the shape or color of a mole on the vulva, discharge from a lesion or sore spot in the vulva, and swollen lymph nodes in the groin area. Several risk factors contribute to vulvar cancer, including increasing age, human papillomavirus (HPV) infection, smoking, inflammatory vulvar conditions, prior pelvic radiation, and immunodeficiency. Diagnosing vulvar cancer can be challenging due to its sometimes nonspecific nature, and other conditions like cutaneous SCC, cutaneous BCC, cutaneous melanoma, and various skin disorders may mimic its symptoms. Surgical excision is the standard treatment for vulvar cancer, while adjuvant radiation and chemotherapy may be recommended based on the histopathology and extent of the disease. Lymphatic spread in vulvar cancer typically involves homolateral superficial inguinal lymph nodes and, later, the deep femoroinguinal lymph nodes. Lymph node status significantly influences overall survival, with lower survival rates observed in patients with lymph node metastasis. Adjuvant radiotherapy can improve progression-free survival in node-positive patients. The recurrence rate of vulvar cancer is 37% at five years, and distant metastasis leads to a poor prognosis. Complications of vulvar cancer may include increased pain and irritation as the malignancy spreads and invades surrounding tissues. Surgical complications are common, such as infection, blood loss, lymphedema in the lower extremities, chronic pain, and organ-related issues during additional procedures. Chemotherapy and radiation can lead to susceptibility to disease, gastrointestinal reactions, tissue fibrosis, and lymphedema.
- In the United States, vulvar cancer accounts for nearly 6% of cancers in female reproductive organs and 0.7% of all cancers in women, with an incidence rate of 2.5 cases per 100,000 women annually.
Thelansis’s “Vulvar Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vulvar Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Vulvar Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Vulvar Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment